Tetrabenazine in the treatment of hyperkinetic movement disorders

References

• Ashcroft GW, Macdougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J. Ment. Sci.107, 287–293 (1961).
   PubMedGoogle Scholar
• Sattes H. The treatment of chorea minor with the monoamine liberator ‘Nitoman’. Psychiatr. Neurol. (Basel). 140, 13–19 (1960).
   PubMedGoogle Scholar
• Stumpf W. Untersuchungen uber ‘Nitoman’. Psychiatr. Neurol. 140, 63–68 (1960).
   Google Scholar
• Brandrup E. Reserpin og tetrabenacin ved chorea Huntington. Nord. Med.4, 968–969 (1960).
   Google Scholar
• Fog R, Pakkenberg H. Combined nitoman-pimozide treatment of Huntington’s chorea and other hyperkinetic syndromes. Acta. Neurol. Scand. 46, 249–251 (1970).
   PubMed Web of Science ®Google Scholar
• Toglia JU, McGlamery M, Sambandham RR. Tetrabenazine in the treatment of Huntington’s chorea and other hyperkinetic movement disorders. J. Clin. Psych.39, 81–87 (1978).
   Google Scholar
• Huang CY, McLeod JG, Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington’s chorea. Med. J. Aust. 1, 583–584 (1976).
   PubMedGoogle Scholar
• Gilligan BS, Wodak J, Veale JL, Munro OR. Tetrabenazine in the treatment of extrapyramidal dyskinesias. Med. J. Aust. 2, 1054–1056 (1972).
   PubMedGoogle Scholar
• Swash M, Roberts AH, Zakko H, Heathfield KW. Treatment of involuntary movement disorders with tetrabenazine. J. Neurol. Neurosurg. Psych. 35, 186–191 (1972).
   PubMedGoogle Scholar
• McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1, 104–107 (1974).
   PubMed Web of Science ®Google Scholar
• Kingston D. Tetrabenazine for involuntary movement disorders. Med. J. Aust. 1, 628–630 (1979).
   PubMed Web of Science ®Google Scholar
• Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 31, 1051–1054 (1981).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann. Neurol.11, 41–47 (1982).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv. Neurol.37, 277–289 (1983).
   PubMedGoogle Scholar
• Gimenez-Roldan S, Mateo D. Huntington’s disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 4, 282–287 (1989).
   PubMedGoogle Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48, 358–362 (1997).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington’s disease-associated chorea. Clin. Neuropharmacol.25, 300–302 (2002).
   PubMed Web of Science ®Google Scholar
• Paleacu D, Paleacu D, Giladi N et al. Tetrabenazine treatment in movement disorders. Clin. Neuropharmacol.27, 230–233 (2004).
   PubMed Web of Science ®Google Scholar
• Huntingtons Study Group. Tetrabenazine as anti-chorea therapy in Huntington’s disease: a randomized controlled trial. Neurology (2005)(In press).
   Google Scholar
• Frank S, Onodo W, Hunter C, et al. A randomized, double-blind, placebo-controlled, staggered withdrawal study in patients with Huntington’s disease treated with tetrabenazine. Ann. Neurol.(In Press) (2005).
   Google Scholar
• Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38, 391–394 (1988).
   PubMed Web of Science ®Google Scholar
• Vieregge P. Tetrabenazine in the treatment of senile vocal tics. J. Neurol. 235, 126–127 (1987).
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ, Garcia-Ruiz PJ. Pharmacological options for the treatment of Tourette’s disorder. Drugs61, 2207–2220 (2001).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Glaze DG, Frost JD Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette’s syndrome. Neurology 34, 688–692 (1984).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette’s syndrome. Can J. Neurol. Sci. 14, 541–546 (1987).
   Google Scholar
• Tarsy D. Tardive Dyskinesia. Curr. Treat. Options Neurol. 2, 205–214 (2000).
   PubMedGoogle Scholar
• Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J. Psych.156, 1279–1281 (1999).
   PubMed Web of Science ®Google Scholar
• Fahn S. A therapeutic approach to tardive dyskinesia. J. Clin. Psych.46, 19–24 (1985).
   Google Scholar
• Scott BL. Evaluation and treatment of dystonia. South. Med. J. 93, 746–751 (2000).
   PubMedGoogle Scholar
• Manji H, Howard RS, Miller DH. et al. Status dystonicus: the syndrome and its management. Brain 121(Pt 2), 243–252 (1998).
   PubMedGoogle Scholar
• Hoehn MM, Cherington M. Spinal myoclonus. Neurology 27, 942–946 (1977).
   PubMedGoogle Scholar
• Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch. Neurol.43, 1025–1031 (1986).
   PubMedGoogle Scholar
• Hunter C, Vuong K, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Neurology 62(Suppl. 5), A506–A507 (2004).
   PubMedGoogle Scholar
• Stacy M, Jankovic J. Tardive tremor. Mov. Disord.7, 53–57 (1992).
   PubMed Web of Science ®Google Scholar
• Storey E, Lloyd J. Tardive tremor. Mov. Disord.12, 808–810 (1997).
   PubMedGoogle Scholar
• Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin. Neuropharmacol.18, 197–214 (1995).
   PubMed Web of Science ®Google Scholar
• Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1- 9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J. Pharmacol. Exp. Ther. 127, 103–109 (1959).
   PubMed Web of Science ®Google Scholar
• Scherman D, Henry JP. Acido–basic properties of the catecholamine uptake inhibitors tetrabenazine and dihydrotetrabenazine. Biochimie 64, 915–921 (1982).
   PubMedGoogle Scholar
• Roberts MS, Watson HM, McLean S, Millingen KS. Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography. J. Chromatogr. 226, 175–182 (1981).
   PubMedGoogle Scholar
• Mehvar R, Jamali F, Watson MW, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug. Metab. Dispos. 15, 250–255 (1987).
   PubMedGoogle Scholar
• Roberts MS, McLean S, Millingen KS, Galloway HM. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur. J. Clin. Pharmacol. 29, 703–708 (1986).
   PubMedGoogle Scholar
• Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur. J. Pharmacol. 102, 425–430 (1984).
   PubMed Web of Science ®Google Scholar
• Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J. Neurochem.47, 331–339 (1986).
   PubMed Web of Science ®Google Scholar
• Pletscher A, Brossi A, Gey K. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int. Rev. Neurobiol.4, 275–306 (1962).
   Web of Science ®Google Scholar
• Lane JD, Smith JE, Shea PA, McBride WJ. Neurochemical changes following the administration of depleters of biogenic monoamines. Life Sci.19, 1663–1667 (1976).
   PubMed Web of Science ®Google Scholar
• Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington’s disease. Neuropharmacology 27, 717–719 (1988).
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Mena MA, Sanchez Bernardos V. et al. Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington’s disease. Clin. Neuropharmacol.18, 58–63 (1995).
   PubMedGoogle Scholar
• Gonzalez AM, Walther D, Pazos A, Uhl, GR. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res. Mol. Brain Res.22, 219–226 (1994).
   PubMedGoogle Scholar
• Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 93, 5166–5171 (1996).
   PubMed Web of Science ®Google Scholar
• Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann. Neurol.12, 257–262 (1982).
   PubMed Web of Science ®Google Scholar
• Reches A, Burke RE, Kuhn CM et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J. Pharmacol. Exp. Ther. 225, 515–521 (1983).
   PubMed Web of Science ®Google Scholar
• Burke R. E, Reches A, Traub MM. et al. Tetrabenazine induces acute dystonic reactions. Ann. Neurol.17, 200–202 (1985).
   PubMedGoogle Scholar
• Tomlinson DR. The mode of action of tetrabenazine on peripheral noradrenergic nerves. Br. J. Pharmacol.61, 339–344 (1977).
   PubMedGoogle Scholar
• Jankovic J, Beach J, Ashizawa T. Emotional and functional impact of DNA testing on patients with symptoms of Huntington’s disease. J. Med. Genet. 32, 516–518 (1995).
   PubMed Web of Science ®Google Scholar
• The Huntington’s DiseaseCollaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72, 971–983 (1993).
   PubMedGoogle Scholar
• McArthur AW, Pollock M, Smidt NA. Combined therapy with tetrabenazine and pimozide in Huntington’s chorea: pilot study. NZ Med. J. 83, 114–116 (1976).
   PubMed Web of Science ®Google Scholar
• Mikkelsen BO. Tolerance of tetrabenazine during long-term treatment. Acta. Neurol. Scand. 68, 57–60 (1983).
   PubMedGoogle Scholar
• Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am. J. Psych. 130, 479–483 (1973).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Vuong K, Hunter C. Safety and efficacy of tetrabenazine in the treatment of Huntington’s disease and other choreas. Mov. Disord.19, 1127 (2004).
   Google Scholar
• Shannon J, Kaplan M, Pierce M. An interesting reaction to a tranquilizer: tonic seizures with perphenazine (Trilofon). Am. J. Psych. 114, 556 (1957).
   PubMedGoogle Scholar
• Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 43, 937–941 (1993).
   PubMed Web of Science ®Google Scholar
• Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South. Med. J. 83, 525–532 (1990).
   PubMed Web of Science ®Google Scholar
• Pasricha P, Sugumar A, Jankovic, J. From disturbed motility to disordered movement: A review of the clinical and legal risks of metoclopramide. Nat. Gastr.(In Press) (2005).
   Google Scholar
• Mejia N, Vuong K, Hunter C, Jankovic J. Medications associated with the onset of tardive dyskinesia. Mov. Disord.20(Suppl. 10), S18 (2005).
   Google Scholar
• Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch. Gen. Psych. 27, 95–99 (1972).
   PubMed Web of Science ®Google Scholar
• Bartels M, Zeller E. Tetrabenazine (Nitoman) therapy of chronic spontaneous oral dyskinesia. A video and EMG-controlled study. Eur. Arch. Psych. Neurosci.234, 172–174 (1984).
   PubMedGoogle Scholar
• Watson MW, Skelton D, Jamali F. Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can. J. Psychiatry 33, 11–13 (1988).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Hunter C, Mejia N, Vuong K. Tetrabenazine: Effective treatment for tardive dyskinesia. Mov. Disord.19(Suppl. 9), S73 (2004).
   Google Scholar
• Simpson G. M. The treatment of tardive dyskinesia and tardive dystonia. J. Clin. Psych.61(Suppl. 4), 39–44 (2000).
   Google Scholar
• Jankovic J. Tourette’s syndrome. N. Engl. J. Med.345, 1184–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Kurlan R, Como PG, Miller P et al. The behavioral spectrum of tic disorders: a community-based study. Neurology 59, 414–420 (2002).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Diagnosis and classification of tics and Tourette syndrome. Adv. Neurol.58, 7–14 (1992).
   PubMedGoogle Scholar
• Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette’s syndrome. Mov. Disord.18, 1530–1533 (2003).
   PubMed Web of Science ®Google Scholar
• Sweet RD, Bruun R, Shapiro E, Shapiro AK. Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Arch. Gen. Psych. 31, 857–861 (1974).
   PubMed Web of Science ®Google Scholar
• Shapiro AK, Shapiro AS, Bruun R. Gilles de la Tourette Syndrome. Raven Press, NY, 212–214 (1978).
   Google Scholar
• Hunter C, Vuong K, Mejia N, Jankovic J. Tetrabenazine, a monoamine depletor, effective in the treatment of Tourette’s syndrome. Mov. Disord.19(Suppl. 9), S437 (2004).
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Frucht SJ. Tetrabenazine in the treatment of severe pediatric chorea. Mov. Disord.18, 703–706 (2003).
   PubMedGoogle Scholar
• Vuong K, Hunter C, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov. Disord.19(Suppl. 9), S422 (2004).
   Google Scholar
• Kidd DW, McLellan DL. Self-poisoning with tetrabenazine. Br. J. Clin. Pract.26, 179–180 (1972).
   PubMedGoogle Scholar
• Hunter C, Wang A, Vuong K, Jankovic J. Age-related tolerability of tetrabenazine. Mov. Disord.17(Suppl. 5), S41 (2002).
   Google Scholar
• Stevens E, Roman A, Houa M, Razavi D, Jaspar N. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med.24, 369–371 (1998).
   PubMedGoogle Scholar
• Burke RE, Fahn S, Mayeux R et al. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington’s disease. Neurology 31, 1022–1025 (1981).
   PubMed Web of Science ®Google Scholar
• Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington’s disease. Clin. Neuropharmacol.15, 63–68 (1992).
   PubMed Web of Science ®Google Scholar
• Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov. Disord.11, 95 (1996).
   PubMed Web of Science ®Google Scholar
• Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov. Disord.12, 246–248 (1997).
   PubMedGoogle Scholar
• McLellan DL. The suppression of involuntary movements with tetrabenazine. Scott. Med. J.17, 367–370 (1972).
   PubMedGoogle Scholar
• Shoulson I, Goldblatt D. Huntington’s disease (HD): effect of tetrabenazine and antipsychotic drugs on motoric features. Neurology 31, 79 (1981).
   Web of Science ®Google Scholar
• Jahan MS, Farooque AI, Wahid Z. Neuroleptic malignant syndrome. J. Natl. Med. Assoc.84, 966–970 (1992).
   PubMed Web of Science ®Google Scholar
• Snaith RP, Warren HD. Letter: Treatment of Huntington’s chorea with tetrabenazine. Lancet 1, 413–414 (1974).
   PubMedGoogle Scholar
• Thiriot DS, Ruoho AE. Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. J. Biol. Chem.276, 27304–27315 (2001).
   PubMedGoogle Scholar